QT Imaging Holdings, Inc. acquires QT Imaging, Inc. (2024)

Deal facts

Buyer: QT Imaging Holdings, Inc.
Target: QT Imaging, Inc.
Deal value: Not disclosed
Announced: 5 March 2024
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares, loan-note

Sources

What we know

QT Imaging Holdings, Inc. and QT Imaging, Inc. have agreed to merge in a transaction valued at undisclosed terms. The deal structure involves consideration through shares and loan notes, with both entities operating within the US healthcare sector. Although the announcement date was recorded as 5 March 2024, the transaction was completed the following day on 4 March 2024, indicating a rapid execution of the merger agreement between the two parties.

This combination represents a strategic consolidation of equals within the medical imaging landscape, facilitated by a mixed consideration package. The parties have successfully finalised the legal and operational integration required to proceed with the merger. The transaction is subject to regulatory approval.

More M&A Tools

Explore the Toolkit

Tools, frameworks and AI assistants designed for entrepreneurs serious about M&A.

Access now

Deal timeline

1 update

4 Mar 2024CompletedClosed
QT Imaging Holdings, Inc. completes acquisition of QT Imaging, Inc.
Introductory Note On March 4, 2024, QT Imaging Holdings, Inc. (f/k/a GigCapital5, Inc. (“ GigCapital5 ”)) (the “ Company ” or “ Combined Company ” or “ QT Imaging Holdings ”) consummated (the “ Closing ”) its business combination (the “ Business Combination ”) with QT Imaging, Inc. (“ QT Imaging ”) pursuant to that certain Business Combination Agreement, dated as of December 8, 2022, by and among
Source

OpinionExit Mode editorial

We see a distinct signal in the US healthcare sector with the completed merger of equals between QT Imaging Holdings, Inc and QT Imaging, Inc, announced on 5 March 2024. This transaction is not a traditional acquisition where a larger entity swallows a smaller one. Instead, it represents a structural alignment of two peers aiming to consolidate capabilities without the friction of a hostile takeover. The deal structure relies entirely on shares and loan notes, meaning no cash changed hands at completion. This is a critical detail for the SME founder watching from the sidelines, as it shifts the risk profile from immediate liquidity to long-term alignment.

The use of loan notes alongside share consideration introduces specific commercial mechanics that founders must understand. Unlike a cash deal that offers certainty, this structure ties the target's value to the future performance of the combined entity. It effectively creates a deferred payment mechanism that depends on the success of the new group. In the US regulatory context, such a merger of equals often requires careful attention to change-of-control covenants and potential anti-trust thresholds, even if the CMA is not the primary regulator here. The absence of a stated value in the public announcement reinforces the idea that the parties are prioritising strategic fit over a fixed price tag, leaving the ultimate valuation to the market's judgment over time.

This approach suggests that in the current healthcare landscape, founders are choosing survival and scale over immediate cash exits. The reliance on debt instruments like loan notes implies that the buyer may be conserving cash reserves for operational needs or R&D, passing the financing risk onto the sellers. For the SME founder, this highlights a shift in leverage. When cash is scarce, equity and debt hybrids become the primary currency of dealmaking. It demands a higher degree of trust in the buyer's management team and a clear understanding of the exit mechanics embedded in the share and loan note agreements.

Your immediate action this week should be to review any existing shareholder agreements or term sheets for clauses governing loan note redemption and share conversion rights. Do not assume a merger of equals guarantees liquidity; verify the specific triggers that allow you to convert your equity into cash or listed shares, and understand the timeline for those events.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2024 deals More merger of equals deals More from QT Imaging Holdings, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

17 February 2026CompletedHealthcare

Apimeds Pharmaceuticals US, Inc. to acquire MindWave

Apimeds Pharmaceuticals US, Inc. and MindWave entered the Exit Mode archive.

Buyer: Apimeds Pharmaceuticals US, Inc.
Target: MindWave
Deal value: Not disclosed
Deal type: merger of equals

Read deal Healthcare deals merger of equals deals United States deals

10 December 2024CompletedHealthcare

Patient Square Capital to acquire Patterson Companies, Inc.

Patient Square Capital and Patterson Companies, Inc. entered the Exit Mode archive.

Buyer: Patient Square Capital
Target: Patterson Companies, Inc.
Deal value: USD 2,800,000,000
Deal type: going private

Read deal Healthcare deals going private deals United States deals

6 November 2024CompletedHealthcare

Space Finco, Inc. to acquire Avid Bioservices, Inc.

Space Finco, Inc. and Avid Bioservices, Inc. entered the Exit Mode archive.

Buyer: Space Finco, Inc.
Target: Avid Bioservices, Inc.
Deal value: Not disclosed
Deal type: going private

Read deal Healthcare deals going private deals United States deals

30 October 2024In reviewHealthcare

NOVO HOLDINGS to acquire CATALENT

NOVO HOLDINGS and CATALENT entered the Exit Mode archive.

Buyer: NOVO HOLDINGS
Target: CATALENT
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

7 August 2024In reviewHealthcare

MIDEUROPA PARTNERS to acquire FAMAR

MIDEUROPA PARTNERS and FAMAR entered the Exit Mode archive.

Buyer: MIDEUROPA PARTNERS
Target: FAMAR
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals In review deals

Buyer history